These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 3043032

  • 21. [Ceftriaxone as a single agent in empirical therapy of infection in patients with hematologic disorders. Hanshin Infection Study Group].
    Kuyama J, Yonezawa T, Kageyama T, Ohyabu H, Kitani T, Taniguchi N, Masaoka T, Shibata H, Yasunaga K, Fujitake H.
    Jpn J Antibiot; 1989 Apr; 42(4):930-7. PubMed ID: 2671427
    [Abstract] [Full Text] [Related]

  • 22. [Treatment with sulbactam/cefoperazone of severe infections in patients with hematological disorders].
    Ohno R, Hotta T, Ogura M, Ohnishi K, Morishita T, Murate T, Okumura M, Tanimoto M, Inoue C, Hamaguchi M.
    Jpn J Antibiot; 1989 Aug; 42(8):1713-9. PubMed ID: 2810734
    [Abstract] [Full Text] [Related]

  • 23. [Clinical evaluation of amikacin by intravenous drip infusion for infections in the field of internal medicine].
    Ito A, Maruta I, Ogawa K, Asada H, Matsuzaki M.
    Jpn J Antibiot; 1985 Aug; 38(8):2108-18. PubMed ID: 4079002
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Experiences with intravenous drip infusion therapy of amikacin for severe infections in patients of hematological disorder].
    Hanada S, Kodama M, Iwahashi M, Uematsu T, Utsunomiya A, Kato Y, Nishioka K, Nomura K, Hashimoto S, Kikuchi H, Matsumoto T, Matsumoto M, Yunoki K.
    Jpn J Antibiot; 1982 May; 35(5):1249-53. PubMed ID: 7131757
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Clinical study on transfer into lung tissue and postoperative prophylactic effect of new cephamycin antibiotics, particularly cefotetan and cefbuperazone].
    Imaizumi M, Niimi T, Uchida T, Kajita M, Takahashi T, Uchida Y, Asaoka M, Amano Y, Ojika T, Abe T.
    Jpn J Antibiot; 1988 Apr; 41(4):437-59. PubMed ID: 3165475
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Therapeutic effect of ticarcillin against severe infection in patients with hematologic malignancy (author's transl)].
    Tsubakio T, Kitani T, Nagai K, Kanamaru A, Horiuchi A, Hasegawa H, Masaoka T, Shibata H, Kawagoe H, Shinohara Y, Yoshioka K, Kitawaki T, Nasu T.
    Jpn J Antibiot; 1981 Nov; 34(11):1451-6. PubMed ID: 7334579
    [Abstract] [Full Text] [Related]

  • 39. [A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases].
    Misawa S, Tsuda S, Taniwaki M, Horiike S, Ariyama Y, Hirakawa K, Ueda Y, Kaneko H, Nakao M, Kashima K.
    Jpn J Antibiot; 1995 Apr; 48(4):514-21. PubMed ID: 7540219
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.